The bone marrow niche is increasingly recognized as heterogeneous with specific subtypes of mesenchymal niche cells governing the development or homeostasis of selective parenchymal hematopoietic subsets. The present review outlines recent efforts in dissecting these microniches regulated by unique cell pairings within the bone marrow and provides an overview of how the bone marrow orchestrates multiple facets of hematopoiesis.
INTRODUCTION
The bone marrow is the sanctuary where hematopoietic stem cells (HSCs) self-renew, differentiate into all cell types of the hematopoietic system, and sustain a lifelong production of blood for the organism. The niche concept was first articulated by Schofield [1] when he noticed that the colony unit forming cells obtained from the spleen (CFU-Ss), despite their multilineage differentiation capacity, were different from the cells obtained from the bone marrow, that they could not reconstitute irradiated mice and had limited passage capacity. He hypothesized that stem cells needed to reside in the bone marrow to maintain their stemness. Once they left the niche, they could become less plastic progenitor cells at the expense of their immortality. Schofield's concept was relatively untested for decades and the critical cellular and molecular components of the specialized microenvironment he proposed have just begun to be unveiled over the last 15 years.
Advancements in lineage-tracing, endogenous celldeletion animal models, and high-resolution microscopy have significantly improved our understanding of the molecular and cellular intricacies that maintain and integrate many activities required to sustain the hematopoietic system. The importance of the bone marrow microenvironment is further highlighted by us [2] and others [3] [4] [5] , showing that mutations in nonhematopoietic niche cells can cause cell-autonomous hematopoietic neoplasia.
Therefore, defining the interdependent functional relationship between the mesenchymal support cells and the parenchymal hematopoietic cells is imperative in understanding bone marrow diseases and may offer new opportunities for niche-based therapeutic intervention. In this review, we will summarize recent discoveries of niche participants essential for hematopoiesis, describe specialized microfunctional units formed by specific niche cells that govern a particular hematopoietic cell process, and provide molecular insights for niche-based selective targeting of hematopoietic regeneration.
OSTEOLINEAGE SUBSETS CREATE SPECIALIZED LYMPHOID NICHES
Osteolineage cells are particularly important for lymphoid cell development. Here we describe that distinct osteolineage cells create unique microniches that support the development of different immune cell types.
OSTEOPROGENITORS SUPPORT B-CELL MATURATION
The bone marrow cavity in which hematopoiesis occurs contains a range of osteolineage cells at different developmental stages, including the most primitive mesenchymal stem cells, the osteoprogenitors, the bone-forming osteoblasts, the lining cells that are adjacent to osteoids, and the terminally differentiated osteocytes. Leveraging well characterized osteolineage cell stage-specifc promoters, we could achieve in-vivo deletion of different subtypes of osteolineage cells in individual mouse models by driving cell type-specific expression of a suicide enabling protein. The protein was the diphtheria toxin receptor so that apoptosis of targeted cells only occurs upon diphtheria toxin administration to the animals, and will only occur in a selected cell population in which the receptor is expressed. Using this selective cell deletion strategy, we demonstrated that loss of a subset of bone lineage cells expressing osterix (Osx) led to a reduction of mature B cells and impaired adaptive immune response [6 && ]. In addition to providing interleukin 7 (IL-7), which is a key cytokine required for B-cell differentiation, Osx þ cells also secrete insulin growth factor 1 (IGF1) to govern B-cell maturation, as mice with Osx-specific deletion of IGF1 failed to transition from pro-B to pre-B cells whereas administration of recombinant IGF1 rescued the B-cell defect in an Osx þ cell-deleted mouse model. Therefore, Osx þ osteolineage cells serve to regulate the maturation of early B lymphoid precursors by promoting pro-B to pre-B cell transition through IGF1 production [6 && ]. Prior studies by other laboratories reported similar defects in B progenitor cell maturation and reduced B-cell number when early osteolineage cells were perturbed, including the Osx þ cells and the cells driven by a 2.3 kb collagen type 1 alpha 1 promoter [Col(I)a2.3 kb] that encompass a wider range of osteolineage subpopulations [7] [8] [9] , or disrupted C-X-C motif chemokine 12 (CXCL12) expression from these cells [10] .
MATURE OSTEOLINEAGE CELLS ARE REQUIRED FOR T LYMPHOPOIESIS
Interestingly, using the same cell deletion strategy but targeting a mature osteolineage population showed a completely different lymphopoietic phenotype. In an independent study, we found that invivo depletion of mature osteocalcin-expressing (Ocn þ ) osteolineage cells in the bone marrow resulted in a loss of T lineage cells in the animals, demonstrating their absolute requirement for T immune cell development [11 && ]. These animals
KEY POINTS
Osx þ osteolineage cells create microniches for B-cell development by producing IGF1 to enable pro-B to pre-B maturation.
Ocn
þ mature osteolineage cells affect T lineage development by specifying early T competent progenitor commitment in the bone marrow through Notch signaling.
CD169
þ macrophages are an essential component of erythroblastic islands, a specialized subcompartment within the bone marrow where the erythroid lineage develops. CD169 þ macrophage promotes erythropoiesis under homeostasis, but antagonizes normal erythropoiesis in disease settings including Polycythemia vera and b-thalassemia.
þ macrophages reduce HSPC mobilization by secreting factors which in turn induce nestin þ and other stromal cells to express the HSC-retaining chemokine, CXCL12.
Megakaryocytes secrete TGFb1 to maintain HSC quiescence under homeostatic conditions, but produce FGF1 and additional molecules to promote HSC expansion upon 5-fluorouracil challenge.
Nonmyelinating Schwann cells maintain HSC quiescence through inducing TGFb production from stromal cells (possibly megakaryocytes).
Sympathetic nervous system controls HSC mobilization. SNS relays adrenergic signals to nestin þ cells, which upregulate CXCL12 and retain HSPCs to the bone marrow niche through CXCL12-CXCR4 interaction.
have decreased T competent common lymphoid progenitors (CLP) with a minimal effect on B-cell biased CLP (Ly6D þ ). In addition, the Ocn þ cell deleted mice failed to generate C-C chemokine receptor type 7 (CCR7)-expressing thymic-seeding progenitor cells, resulting in a lack of progenitor T cells capable of homing to a functional thymus, and thereby impacting downstream T-cell production. Ocn þ osteolineage cell appears to regulate T lineage development by communicating with the CLPs through Notch signaling, because the T lymphopenic effect seen in the Ocn þ cell depleted animals could be recapitulated in several mouse models by selective deletion of the delta-like protein 4 (DLL4) expression in Ocn þ cells, or of its receptor and downstream signaling molecules in primitive hematopoietic cells. Another laboratory deleted terminally differentiated osteolineage cells, the osteocytes, in an independent mouse model and reported systemic disruption of metabolism and similar loss of T cells [12] , albeit by a different mechanism including marked metabolic and thymic abnormalities. Therefore, mature Ocn þ osteolineage cells in the bone marrow are indispensible for T-cell regeneration by ensuring the production of early T competent progenitor cells. In addition to CLPs. This cell-cell communication ensures adequate production of T-cell competent CLPs (Ly6D-CLPs) and the expression of chemotactic molecules, CCR7 and PSGL1, on T progenitor cell surface necessary for subsequent thymic seeding and downstream T-cell development. HSC, hematopoietic stem cell; MPP, multipotent progenitor; CLP, common lymphoid progenitor; ETP, early T-cell precursor; DN, double negative; DP, double positive; SP, single positive; DLL4, delta-like 4; IL7, interleukin 7; IGF1, insulin-like growth factor 1; CCR7, C-C chemokine receptor type 7; PSGL1, P-selectin glycoprotein ligand-1.
supporting lymphoid cell development, Ocn þ cells also play important roles in other hematopoietic settings. For instance, in studies where Ocn-expressing cells were depleted, granulocyte colony-stimulating factor (G-CSF)-induced hematopoietic stem and progenitor cell (HSPC) mobilization was markedly compromised [13] . Therefore, Ocn þ cell also controls the traffic of HSPCs in a G-CSF-dependent manner.
Together, these studies show that early-and latestage osteolineage cells play very different roles in supporting B and T lymphopoiesis. Although Osx þ osteolineage cells produce IGF1 that support the maturation of B-cell progenitors, mature Ocn þ cells distinctly affect T-cell specification in the bone marrow (Fig. 1) . These studies redefine bone cells as important immune participants that regulate specific production of cells of the adaptive immune system. The emerging model is one of a highly interrelated system with pairings of mesenchymal support cells with parenchymal lineage committed hematopoietic progenitors to create distinctive functional units to regulate lymphopoiesis. Of particular interest is whether the perturbation of these lymphoid niches is contributing to impaired immune response in pathological settings such as osteoporosis, multiple myeloma, or the lack of T-cell generation postallogeneic bone marrow transplantation. Future directions will involve exploring these heterologous cell interactions in malignant processes such as lymphoma, leukemia, and bone metastatic processes.
ERYTHROBLASTIC ISLANDS ARE MICROFACTORIES FOR RED BLOOD CELLS
Erythroblastic islands are highly specialized subcompartments within the bone marrow where intercellular interactions, in concert with stimulatory and inhibitory cytokines, play critical roles regulating erythropoiesis. Erythroid islands were first described by Bessis [14] . These islands consisted of one or more synchronously maturing cohort of erythroid cells undergoing four or five divisions between proerythroblast and normoblast. Each island was centered on a macrophage, with large areas of closely opposed erythroblast and macrophage membranes. At the conclusion of terminal differentiation, expelled nuclei were phagocytosed by the central macrophage (Fig. 2) . Despite this prophetic description of erythroid niches, these findings did not elicit further insights until recently. A key component of the eyrthroid islands is the central macrophage. Island macrophages are derived from monocyte precursors and likely to be a specialized subset of resident macrophages. The bone marrow contains a heterogeneous population of macrophages at various differentiation stages with diverse phenotypes. Despite prior studies that perturbed macrophage differentiation and observed impaired red blood cell production, the specific identification of the island macrophage has remained elusive. A recent study revealed that specific depletion of CD169 þ macrophages in mice reduced the number of erythroblasts in the bone marrow but did not lead to overt anemia under homeostatic conditions. However, in the case of hemolytic anemia, CD169 þ macrophage depletion led to myeloablation, impaired erythropoietic recovery, and eventually acute blood loss [15] . Interestingly, in a JAK2(V617F)-driven mouse model of polycythemia vera and b-thalassemia, macrophage deletion normalized the erythroid compartment and reduced disease pathology [16] . As can be seen, macrophages can play opposite roles in governing erythropoiesis depending on the physiological conditions. Additional research is needed to understand how macrophages maintain red blood cell production under normal and pathological settings.
A GUARDIAN OF HEMATOPOIETIC STEM AND PROGENITOR CELL TRAFFICKING -THE MACROPHAGE
Another role of the macrophage is to mediate HSC mobilization through signaling the mesenchymal stromal cells. In studying the mobilization of HSCs into the bloodstream in response to G-CSF, investigators found that there was concomitant loss of macrophages and reduced bone formation [17] . In-vivo depletion of macrophages, in either macrophage Fas-induced apoptosis (Mafia) transgenic mice or by administration of clodronate-loaded liposomes into wild type mice, led to marked reduction of endosteal osteoblasts and HSC mobilization into blood, mimicking the phenotype observed during G-CSF administration. Specifically, it is the CD169 þ macrophage but not the Gr-1 hi monocyte that promotes the retention of HSCs in the endosteal niche. CD169 þ macrophage secretes oncostatin M (OSM), which in turn induces nestin þ cells and possibly other mesenchymal stromal cells to express CXCL12 via a mitogen-activated protein kinase kinase-p38-signal transducer and activator of a transcription 3-dependent pathway [18, 19] . CXCL12 engagement with CXCR4 receptor on the HSC surface is crucial for HSC retention in the bone marrow niche. In mice and patients with diabetes, there were increased CD169 þ macrophages and elevated OSM in the bone marrow, and reduced HSC mobilization. OSM neutralization [19] and CXCR4 antagonist [18] in diabetic mice have been shown to improve G-CSF induced HSC mobilization, suggesting that targeting CD169
þ macrophages or antagonizing OSM may be a strategy to restore niche function, particularly in diabetic settings.
Overall, these studies show that macrophages are an indispensible cellular participant needed for HSC retention in the bone marrow, through signaling other bone marrow stromal cells, and also serve as a niche cell population that supports erythropoiesis. The macrophage studies are excellent examples illustrating the concept of one cell type playing multiple roles in supporting different hematopoietic cell processes in the bone marrow, through very different mechanisms.
A QUIESCENT GATEKEEPER FOR HEMATOPOIETIC STEM CELLS -THE MEGAKARYOCYTE
Prior studies have indirectly eluded that the megakaryocyte, originated from hematopoietic lineage and responsible for plate production, regulates HSC activities. These evidence include that transplanted HSCs preferentially lodge within two cell diameters from megakaryocytes near the endosteum [20] , and pharmacological inhibition of megakaryocytic function impairs HSC engraftment [21] . Megakaryocytes appear to participate in hematopoietic recovery posttransplantation through stimulating the proliferation of osteolineage cells [21, 22] and producing thrombospondin, platelet-derived growth factor, and fibroblast growth factor (FGF) 2, which are important factors for the regulation of vasculature following bone marrow damage [23] . However, two recent studies provide strong mechanistic insights demonstrating how megakaryocytes directly regulate HSC quiescence and proliferation under normal and injury conditions. One group selectively depleted megakaryocytes in vivo using Cxcl4-Cre driving inducible diphtheria toxin receptor expression in megakaryocytes in transgenic mice [24 && ]. Both megakaryocyte-depleted mouse models and Cxcl4 complete knockout mice have an increased number of proliferating HSCs, marked by 5-bromo-2-deoxyuridine staining. However, administration of recombinant Cxcl4 into the megakaryocyte-depleted animals only partially rescued HSC numbers and proliferation [24 && ], suggesting that additional factors likely contribute to megakaryocyte-mediated HSC quiescence.
In an independent study, Zhao et al. endogenously ablated megakaryocytes using a different promoter, Pf4-Cre, to drive inducible diphtheria toxin receptor expression on megakaryocytes (Pf4-Cre;iDTR). This version of a megakaryocyte-ablated mouse model also exhibited increased HSC activation and proliferation, and the authors attributed the effect to transforming growth factor beta 1 (TGFb1) because conditional deletion of TGFb1 in megakaryocytes similarly enhanced HSC proliferation. In contrast, TGFb1 injection into megakaryocyte-deleted animals restored HSC quiescence [25 && ]. However, when the very same mouse model was challenged by 5-fluorouracil, a chemotherapeutic agent, HSCs from these mice were defective in expansion and failed to reconstitute recipients upon transplantation. The authors found that the loss of HSC number in stressed megakaryocyte-ablated mice could be rescued by another molecule, FGF1, but the engraftment capacity of these HSCs could not be restored. These interesting data support the hypothesis that under normal homeostatic condition, megakaryocytes maintain HSC quiescence by secreting TGFb1, but upon chemotherapeutic challenge, megakaryocytes secrete FGF1 and additional molecules yet to be identified, to promote HSC expansion and to maintain a fully functional pool of HSCs.
As described, megakaryocytes constitute a specialized microenvironment that maintains the quiescence and proliferation of HSCs. These studies further illustrate that under stress conditions such as chemotherapy, the role of megakaryocytes may switch from a gatekeeper of quiescence to an advocate of HSC expansion.
A STRESS SENSOR FOR THE HEMATOPOIETIC CELLS -THE SYMPATHETIC NERVOUS SYSTEM
Sensory and autonomic innervation of the bone marrow not only regulates physiological homeostatic trafficking of hematopietic cells but also enables them to respond to acute stress signals. HSCs and progenitors circulate in the bloodstream under homeostatic conditions, exhibiting robust circadian fluctuations in antiphase with the expression of the chemokine CXCL12 by stromal cells in the bone marrow niche. Sympathetic tone delivered by nerves in the bone marrow is transmitted to stromal cells through the b(3)-adrenergic receptor, leading to reduced Sp1 transcription factor and the rapid downregulation of CXCL12 expressed by these stromal cells [26] . As such, the cyclical circadian release of HSCs into the bloodstream and the concomitant reduction of CXCL12 in the bone marrow microenvironment are maintained by core genes of the molecular clock through noradrenaline secretion by the sympathetic nervous system (SNS).
The concept that signals from the SNS are critical for HSPC egress from the bone marrow was illustrated by several studies using complementary mouse models targeting this pathway. In one study, nonmyelinating Schwann cells were proven to be responsible for maintaining HSC hibernation through inducing TGFb production from stromal cells. Mice with autonomic nerve denervation, reduced number of TGFb-producing cells, or TGFb type II receptor-deficient HSCs all exhibited reduced levels of Smad activation in HSCs, loss of HSCs from the bone marrow, and impaired long-term repopulation activity [27] . In a different study, UDPgalactiose ceramide galactosyltransferase-deficient (Cgt À/À ) mice exhibited aberrant nerve conduction and displayed no HSPC egress from the bone marrow following G-CSF or fucoidan administration [28] . Pharmacological or genetic ablation of adrenergic neurotransmission in mice indicates that norepinephrine signaling controls G-CSF-induced osteolineage cell suppression, CXCL12 downregulation from stromal cells, and HSPC mobilization. In contrast, administration of a b(2) adrenergic agonist enhances mobilization in both norepinephrinedeficient and control mice, suggesting that the sympathetic nervous system is responsible for the attraction of stem cells to their niche. It was found in later studies that the cells that relay the adrenergic signals from the SNS to HSPCs appear to be nestin þ mesenchymal cells, as in-vivo nestin þ cell depletion significantly reduces bone marrow homing of HSPCs [29] .
It is known that some diabetic patients fail to achieve sufficient CD34 þ HSPCs upon G-CSF stimulation. Using mouse models of type 1 (streptozotocin-induced) and type 2 (db/db) diabetes, scientists found that HSPCs that were unable to egress upon G-CSF treatment and localized aberrantly in the bone marrow space with altered pattern of catecholaminergic nerve termini [13] . This altered sympathetic innervation was associated with decreased sensitization of b-adrenergic receptor in nestin-GFP þ cells, which in turn was unable to downmodulate CXCL12 in response to G-CSF treatment. The HPSC mobilization defect in diabetic mouse models can be rescued by pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the receptor antagonist AMD3100 [13] .
In essence, these studies described an unprecedented pathway of mesenchymal cell control of stem cell trafficking -through the SNS. Sympathetic nerve fibers were indispensible players in relaying signals from the niche cells to the HSCs and regulating stem cell trafficking during hibernation, circadian oscillation, and G-CSF-induced mobilization. These data offer new intervention opportunities to overcome poor HPSC mobilization in clinical and disease settings including diabetes.
CONCLUSION
In summary, recent advancement in technologies enabled unprecedented precision in pinpointing stromal components that support specific aspects of hematopoietic development and maintenance. The common denominator of these discoveries is that each 'stromal' cell type affects a very specific parenchymal hematopoietic cell subset development or activities. The emerging picture of the bone marrow niche is a highly complex, integrated ensemble of numerous microniches each specialized in unique hematopoietic functions and responding differently to stress or injuries. The potential of unraveling niche contribution to normal and disease physiology is substantial with the new tools at hand. It is anticipated that with better understanding of what specific subsets of hematopoietic cells are governed by what stromal elements, the ability to engineer a particular hematopoietic outcome will become feasible. Furthermore, how the niche contributes to hematologic malignancies or bone marrow disease remains largely unexplored. Is there competition of anatomical space or niche resources between normal and malignant cells? Is there a hierarchy of components in the niche that confers cancer cell survival? Can specific intervention of these niche interactions improve therapeutic outcome? Gaining a 'systems' level understanding of the hematopoietic bone marrow may provide useful paradigms for studying other tissue niches with the long-term goal of ultimately manipulating better regenerative processes in contexts of disease.
